Similar Datasets
Project description:Glycine max x Glycine soja overview
| PRJNA1338322 | ENA
Project description:These data belong to a metabolic engineering project that introduces the reductive glycine pathway for formate assimilation in Cupriavidus necator. As part of this project we performed short-term evolution of the bacterium Cupriavidus necator H16 to grow on glycine as sole carbon and energy source. Some mutations in a putiative glycine transporting systems facilitated growth, and we performed transcriptomics on the evolved strain growing on glycine. Analysis of these transcriptomic data lead us to the discovery of a glycine oxidase (DadA6), which we experimentally demonstrated to play a key role in the glycine assimilation pathay in C. necator.
2020-06-06 | GSE151887 | GEO
Project description:While glucose–lipid metabolic remodeling is a major driver of cardiomyocyte proliferative decline, the role of amino acid metabolism in cardiac generation remains poorly understood. Here, we identify glycine as a previously unrecognized pro-proliferative metabolic regulator in mammalian cardiomyocytes. Notably, exogenous glycine supplementation significantly enhanced cardiomyocyte proliferation in both neonatal and adult models, while also demonstrating enhanced efficacy in promoting cardiac repair following myocardial infarction. Mechanistically, glycine activated PI3K–AKT signaling through the amino acid sensor GCN2 and weakened the GCN2–AKT association, thereby facilitating AKT phosphorylation and enabling cardiomyocyte cell cycle re-entry. To address the pharmacokinetic limitations of free glycine administration, specifically its high peak concentration and suboptimal biodistribution profiles, we developed a cardiac-targeted liposomal nanoformulation (LNP@glycine) that exhibited enhanced myocardial accumulation efficacy, reduced dosing requirements, and further improved therapeutic efficacy. Collectively, our findings reveal glycine as a novel metabolic regulator of heart regeneration and highlight a translatable strategy that integrates amino acid-specific metabolic modulation with precision targeted delivery for ischemic heart disease.
2026-02-06 | GSE318305 | GEO